Accelerate to discover
Related topics
Early immune response in mice immunized with inactivated vaccine against SARS-CoV-2
Nov 19, 2020
The development of a vaccine against COVID-19 is a hot topic for many research laboratories all over the world. Our aim...
Bruker announces software provider PMOD Technologies LLC
Nov 13, 2020
PMOD Technologies aims to equip researchers with best-in-class software tools for biomedical imaging research in humans...
Microvascular injury in mild traumatic brain injury accelerates alzheimer-like pathogenesis in mice
Nov 9, 2020
Traumatic brain injury (TBI) is considered as the most robust environmental risk factor for Alzheimer’s disease (AD)....
Discover the new NovoCyte Penteon - when exceptional performance meets simplicity
Nov 6, 2020
The NovoCyte Penteon flow cytometer builds on its successful predecessor, the NovoCyte. You now have the flexibility to...
Live animal imaging - Humane animal research
Oct 26, 2020
Drawing on over 50 years of expertise in the life and animal sciences, Bruker designs preclinical imaging systems that...
Meet the Expert - Brent Barre interview
Oct 21, 2020
Learn what a researcher at the forefront of COVID-19 research has to say about his current research environment.
Easy and accurate cell counting in less than 20 seconds with C100 counter
Oct 16, 2020
Cell counters are tools for counting live and/or dead cells in a culture. Any researcher who works in a cell culture...
Automated fever & hypothermia detection
Oct 14, 2020
As one of the oldest clinical indicators of disease in mammals, temperature is a crucial parameter to monitor,...
May 18, 2016
With the increasing need for new therapies for cancer, autoimmune disorders and Alzheimer’s disease, monoclonal antibodies are proving very successful due to their high affinity and specificity for their target antigens. In cancer, for example, their first use was as antagonists of oncogenic receptor tyrosine kinases, but today monoclonal antibodies have emerged as vehicles for the targeted delivery of potent chemotherapeutic agents and as powerful tools to manipulate anticancer immune responses. Currently,
more than 30 antibody therapeutics are marketed worldwide. Some analysts predict that, given the rate of current revenue growth and potential new approvals, the global market could reach $58 billion by 2016. In addition, there are hundreds of monoclonal antibody-based biologic drugs in various phases of clinical trials worldwide.
Get more info
Brand profile
IntelliCyt Corporation's high throughput flow technology is the first to enable screening suspension cells, beads, microbes and mixtures.
More info at:
www.intellicyt.com/
BioFocus newsletter
Register to receive Brand new technology development, Important product updates, Interesting scientific events and more!
BioTech a.s. © 2014
Designed & developed by imagineit
Technologies
